CTCFL and cancer: BORIS expression in cancer cells is associated with stemness [14], invasiveness [18, 19], increased epithelial to mesenchymal transition (EMT) [20], resistance to anticancer treatment [21], activation of oncogenes or other CTAs [22, 23], and regulation of humanoid-specific SVA transposable elements [24].